Cardiovascular diseases (CVDs), one of the world’s leading causes of death, claim as many as 17.9 million lives each year globally. According to a study by the Indian Council of Medical Research and Registrar General of India, India accounts for approximately 60% of the global burden of heart disease. Additionally, the study highlights a high prevalence of hypertension in the country, with as much as 30% of the population affected. Notably, 62.5% of newly diagnosed hypertensive individuals have high sympathetic overactivity. The study further found that there is a significant lack of awareness, treatment, and control of high blood pressure among young adults with hypertension.

Amongst the armamentarium of drugs for the management of cardiac disease, the advent of selective beta-blockers has transformed cardiovascular medicine by providing clinicians with a range of tailored treatment options. These medications have revolutionised the management of hypertension, angina, and heart failure by specifically targeting beta-1 receptors while minimising adverse effects on other physiological systems.

The journey of beta-blocker development began in the mid-20th century when scientists delved into understanding the role of the sympathetic nervous system in cardiovascular function. A significant milestone in beta-blocker development occurred in the 1950s when James W. Black and his colleagues focused on receptor pharmacology, aiming to identify compounds that could alone block the beta-adrenergic receptor subtype. In the early 1960s, Black and his team developed a molecule called propranolol, which later paved the way for more cardio (beta-1 receptors in the heart)-selective and convenient beta-blockers like bisoprolol.

Bisoprolol, for instance, has gained the trust of patients worldwide for over 3 decades. It is widely utilised as a reliable and well-established medication in the management of various conditions. Its selectivity for beta-1 receptors made it a favourable choice in patients with concomitant respiratory conditions.

The most prominent question that arises in our mind is how beta-blockers work. These medications exert their effects by blocking the release of stress hormones, such as adrenaline and noradrenaline, in specific areas of the body. As a result, they slow down the heart rate and decrease the force with which blood is pumped throughout the body. Additionally, beta blockers can inhibit the production of a hormone called angiotensin II by the kidneys, contributing to the significant lowering of blood pressure.

Researchers and cardiologists have found strong evidence that taking a beta blocker after a heart attack decreases the chances of early death by 44%. Beta-blockers are also known to improve long-term outcomes in heart failure, blood pressure control and coronary diseases. Beta-blockers have been extensively used globally, and the cardio-selective ones are known to be well tolerated in most patients, leading to high compliance among patients.

Therefore, we, at Merck, on this day, pay our tributes to Sir James Whyte Black for the novel discovery of Beta-blockers on his 99th birth anniversary. (14 June 1924 – 22 March 2010).Here is what the doctors have to say:

Dr Jamshed J Dalal, Mumbai, said, “Beta blockers are important drugs in the management of the whole spectrum of cardiovascular disease. They are used in the treatment of hypertension, heart failure, coronary artery disease, cardiomyopathies and arrhythmias. Indians have a higher heart rate than Westerners, and beta blockers help stabilise it. They not only relieve symptoms but often improve survival. They are also used for tremors, migraine and glaucoma. They have been extensively used in India for many decades and helped millions of people. For this, we owe gratitude to Sir James Black, who developed this molecule.”Dr J C Mohan, Delhi, said, “Bisoprolol represents the best-in-class beta blocker with strong evidence and least side effects. Its ease of use, compliance, and adherence are remarkable.”
Dr Arup Dasbiswas, Kolkata, said, “India is the world capital of cardiovascular disease (CVD), and CVD is the leading cause of death. Beta-blockers, particularly highly cardio-selective beta blockers like bisoprolol, are very useful drugs, reducing the effects of sympathetic hyperactivity. Beta-blockers are a class of medications that block the effects of adrenaline and related stress hormones. They are commonly prescribed to treat high blood pressure, fast heart rates, heart rhythm disorders, angina, and heart failure. After a heart attack, they decrease mortality and further events. Bisoprolol has more good effects and less of side effects.”

Dr Jayagopal P B, Palakkad, said, “One of the biggest breakthroughs in the therapy of angina, hypertension, and cardiovascular disease, has been the advent of beta-blockers in the market. Undoubtedly, beta-blocker therapy has been a blessing for patients with angina. Following heart attacks, the efficacy is well established. This is one of the guideline-directed medical therapy for reducing death and hospital admissions. Bisoprolol, introduced as the beta-blocker of choice in smokers, is indeed a very effective agent. Its long duration of action and safety in patients with diabetes, dyslipidemia and kidney disease makes it one of the most desirable agents. This is my preferred beta-blocker in cardiac patients.”

Disclaimer: The views and opinions expressed in the story are independent professional judgement of the experts and we do not take any responsibility for the accuracy of their views. This should not be considered as a substitute for medical advice. Please consult your treating physician for more details. The above is non-editorial content and ET does not guarantee, vouch or endorse any of the above content, nor is it responsible for them in any manner whatsoever. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified.